CLINICAL PERSPECTIVES: Open-Label Extension Study Testing Arimoclomol in Patients With NPC +++ +++ +++

Real-World Outcomes of Arimoclomol in Patients With Niemann Pick Type C https://checkrare.com/real-world-outcomes-of-arimoclomol-in-patients-with-niemann-pick-type-c/ Caroline Hastings, MD, Pediatric Hematology Oncology, Professor of Pediatrics at the University of California, San Francisco, discusses real-world outcomes of arimoclomol in patients with Niemann Pick type C (NPC). Age-Stratified Clinical Burden of Post-Allogeneic HSCT Complications in Hurler Syndrome (MPS IH) https://checkrare.com/age-stratified-clinical-burden-of-post-allogeneic-hsct-complications-in-hurler-syndrome-mps-ih/ Ali Mohajer, PhD, Qral Group, discusses the age-stratified burden of post-allogeneic hematopoietic stem cell transplantation (post-allo-HSCT) complications in Hurler syndrome (MPS IH). Uplizna (inebilizumab): A First-In-Class Approach to Generalized Myasthenia Gravis Treatment https://checkrare.com/uplizna-inebilizumab-a-first-in-class-approach-to-generalized-myasthenia-gravis-treatment/ Richard Nowak, MD, Director of the Myasthenia Gravis Clinic at Yale University, discusses the recent U.S. Food and Drug Administration (FDA) approval of Uplizna (inebilizumab) for the treatment of patients with generalized myasthenia gravis (gMG). Rare Diseases in Ireland – New Efforts to Improve Access to Care https://checkrare.com/rare-diseases-in-ireland-new-efforts-to-improve-access-to-care/ Each country takes a different approach to rare diseases, from the way it defines the term to the health policies it implements to its approach to research. Open-Label Extension Study Testing Arimoclomol in Patients With NPC https://checkrare.com/open-label-extension-study-testing-arimoclomol-in-patients-with-npc/ A recent paper published in Molecular Genetics and Metabolism presented safety and efficacy outcomes from the 48-month open-label extension of the NPC-002 study of arimoclomol in patients with Niemann-Pick type C (NPC). FDA Grants Fast Track Designation to Myasthenia Gravis Therapy https://checkrare.com/fda-grants-fast-track-designation-to-myasthenia-gravis-therapy/ Jan Klatt, MD, Head of Development Unit Neurology & Immunology, Merck Healthcare, Germany, discusses the U.S. Food and Drug Administration’s (FDA) Fast Track designation of cladribine capsules for patients with generalized myasthenia gravis (gMG). Post Hoc Analysis of Long-Term Efficacy of Migalastat in Females With Fabry Disease https://checkrare.com/post-hoc-analysis-of-long-term-efficacy-of-migalastat-in-females-with-fabry-disease/ A recent post hoc analysis of long-term efficacy of migalastat in female patients with Fabry disease was published in the Journal of Medical Genetics. Current Trends in the Healthcare Job Market https://checkrare.com/current-trends-in-the-healthcare-job-market/ Vicki Salemi, Career Expert, discusses current trends in the healthcare job market and expectations for 2026. Duchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD) Recommended Uniform Screening Panel https://checkrare.com/duchenne-muscular-dystrophy-dmd-and-metachromatic-leukodystrophy-mld-recommended-uniform-screening-panel/ The U.S. Department of Health and Human Services (HHS) has approved the addition of Duchenne muscular dystrophy (DMD) and metachromatic leukodystrophy (MLD) to the Recommended Uniform Screening Panel.